JP2019505549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505549A5 JP2019505549A5 JP2018543362A JP2018543362A JP2019505549A5 JP 2019505549 A5 JP2019505549 A5 JP 2019505549A5 JP 2018543362 A JP2018543362 A JP 2018543362A JP 2018543362 A JP2018543362 A JP 2018543362A JP 2019505549 A5 JP2019505549 A5 JP 2019505549A5
- Authority
- JP
- Japan
- Prior art keywords
- pros
- syndrome
- disorder
- composition according
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000035871 PIK3CA-related overgrowth syndrome Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010062344 Congenital musculoskeletal anomaly Diseases 0.000 claims 1
- 206010027145 Melanocytic naevus Diseases 0.000 claims 1
- 208000007256 Nevus Diseases 0.000 claims 1
- 208000012868 Overgrowth Diseases 0.000 claims 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims 1
- 244000223014 Syzygium aromaticum Species 0.000 claims 1
- 208000009443 Vascular Malformations Diseases 0.000 claims 1
- 229950010482 alpelisib Drugs 0.000 claims 1
- 206010039722 scoliosis Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022012963A JP2022058800A (ja) | 2016-02-19 | 2022-01-31 | ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ） |
| JP2024107982A JP2024125429A (ja) | 2016-02-19 | 2024-07-04 | ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ） |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305193.1 | 2016-02-19 | ||
| EP16305193 | 2016-02-19 | ||
| PCT/EP2017/053587 WO2017140828A1 (en) | 2016-02-19 | 2017-02-17 | Byl719 (alpelisib) for use in the treatment of pik3ca-related overgrowth spectrum (pros - cloves syndrome) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022012963A Division JP2022058800A (ja) | 2016-02-19 | 2022-01-31 | ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ） |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019505549A JP2019505549A (ja) | 2019-02-28 |
| JP2019505549A5 true JP2019505549A5 (enExample) | 2020-02-27 |
| JP7051693B2 JP7051693B2 (ja) | 2022-04-11 |
Family
ID=55409795
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543362A Active JP7051693B2 (ja) | 2016-02-19 | 2017-02-17 | ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ） |
| JP2022012963A Pending JP2022058800A (ja) | 2016-02-19 | 2022-01-31 | ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ） |
| JP2024107982A Pending JP2024125429A (ja) | 2016-02-19 | 2024-07-04 | ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ） |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022012963A Pending JP2022058800A (ja) | 2016-02-19 | 2022-01-31 | ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ） |
| JP2024107982A Pending JP2024125429A (ja) | 2016-02-19 | 2024-07-04 | ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ） |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11433059B2 (enExample) |
| EP (1) | EP3416642A1 (enExample) |
| JP (3) | JP7051693B2 (enExample) |
| KR (1) | KR20180115297A (enExample) |
| CN (3) | CN118477076A (enExample) |
| AU (3) | AU2017219834B2 (enExample) |
| CA (1) | CA3013845C (enExample) |
| WO (1) | WO2017140828A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3294314A4 (en) | 2015-05-15 | 2019-01-16 | Memorial Sloan Kettering Cancer Center | USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES |
| CN118477076A (zh) | 2016-02-19 | 2024-08-13 | 国家医疗保健研究所 | 用于治疗pik3ca相关过度生长综合征群的方法 |
| MA54907A (fr) | 2019-02-06 | 2022-05-11 | Venthera Inc | Inhibiteurs de phosphoinositide 3-kinase topiques |
| WO2025045915A1 (en) * | 2023-08-29 | 2025-03-06 | Institut National de la Santé et de la Recherche Médicale | Methods for inducing muscle hypertrophy |
| WO2025045129A1 (zh) * | 2023-08-30 | 2025-03-06 | 广州嘉越医药科技有限公司 | 化合物用于治疗pros谱系疾病的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101583357B (zh) * | 2006-08-29 | 2013-03-20 | 新加坡国立癌症中心 | Mtor拮抗剂和血管生成抑制剂用于制备治疗癌症的药物的用途 |
| AR082418A1 (es) * | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
| SG11201507730UA (en) * | 2013-03-21 | 2015-10-29 | Novartis Ag | Combination therapy comprising a b-raf inhibitor and a second inhibitor |
| EP3294314A4 (en) | 2015-05-15 | 2019-01-16 | Memorial Sloan Kettering Cancer Center | USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES |
| CN118477076A (zh) | 2016-02-19 | 2024-08-13 | 国家医疗保健研究所 | 用于治疗pik3ca相关过度生长综合征群的方法 |
-
2017
- 2017-02-17 CN CN202410563611.0A patent/CN118477076A/zh active Pending
- 2017-02-17 CN CN201780011659.9A patent/CN109562103A/zh active Pending
- 2017-02-17 JP JP2018543362A patent/JP7051693B2/ja active Active
- 2017-02-17 CN CN202410562274.3A patent/CN118477075A/zh active Pending
- 2017-02-17 US US15/998,950 patent/US11433059B2/en active Active
- 2017-02-17 CA CA3013845A patent/CA3013845C/en active Active
- 2017-02-17 WO PCT/EP2017/053587 patent/WO2017140828A1/en not_active Ceased
- 2017-02-17 AU AU2017219834A patent/AU2017219834B2/en active Active
- 2017-02-17 EP EP17705872.4A patent/EP3416642A1/en active Pending
- 2017-02-17 KR KR1020187026976A patent/KR20180115297A/ko not_active Ceased
-
2022
- 2022-01-31 JP JP2022012963A patent/JP2022058800A/ja active Pending
- 2022-04-14 US US17/721,067 patent/US12427141B2/en active Active
- 2022-09-21 AU AU2022235569A patent/AU2022235569B2/en active Active
-
2024
- 2024-07-04 JP JP2024107982A patent/JP2024125429A/ja active Pending
- 2024-12-19 AU AU2024278598A patent/AU2024278598A1/en active Pending
-
2025
- 2025-05-16 US US19/210,131 patent/US20250339417A1/en active Pending
- 2025-06-04 US US19/227,991 patent/US20250295645A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019505549A5 (enExample) | ||
| CN103717571B8 (zh) | 9‑氨基甲基取代的四环素类化合物 | |
| JP2015120736A5 (enExample) | ||
| JP2018035160A5 (enExample) | ||
| EA201690962A1 (ru) | Составы | |
| WO2015028969A3 (en) | Transduction buffer | |
| JP2015512936A5 (enExample) | ||
| JP2015096530A5 (enExample) | ||
| WO2016070151A8 (en) | Methods and compositions relating to microbial treatment and diagnosis of disorders | |
| WO2016164763A8 (en) | Compositions and methods for treating cns disorders | |
| EA201291147A1 (ru) | Анти-c5a-антитела и способы применения антител | |
| CN108026053A8 (zh) | 作为mIDH1抑制剂的稠合的咪唑类化合物 | |
| JP2015500223A5 (enExample) | ||
| ZA202105111B (en) | Pharmaceutical composition for the treatment of pulmonary arterial hypertension | |
| HK1254779A1 (zh) | 抗rsv融合前f蛋白的免疫球蛋白单可变结构域抗体 | |
| JP2017505809A5 (enExample) | ||
| JP2017524633A5 (enExample) | ||
| SG11202105995QA (en) | Co-crystal of ketoprofen, compositions comprising the same, process of producing the same, and uses thereof | |
| WO2015001541A3 (en) | Pharmaceutical film composition | |
| WO2015052568A3 (en) | Solid forms of curcumin and derivatives thereof | |
| JP2019528267A5 (enExample) | ||
| JP2009505991A5 (enExample) | ||
| WO2017168454A3 (en) | Novel compounds as btk inhibitors | |
| JP2017517574A5 (enExample) | ||
| WO2017029642A3 (en) | Novel polymorphs of dolutegravir and salts thereof |